Generys Biopharmaceuticals

Generys Biopharmaceuticals is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of next-generation therapies for metabolic diseases. The company's primary focus is on multi-target peptide drugs, specifically targeting the GLP-1, GIP, and Glucagon receptors to treat conditions such as obesity, type 2 diabetes, and MASH. Its lead candidate, GNS-001, is a long-acting triple agonist designed to provide superior weight loss and glycemic control compared to existing mono- or dual-agonists. Generys leverages a proprietary peptide engineering platform to optimize the pharmacological properties of its candidates, including potency and half-life. The company is backed by prominent venture capital firms including Qiming Venture Partners and TF Capital. Generys aims to address the growing global burden of metabolic disorders through innovative biologics that offer improved efficacy and safety profiles.